An observational study in Dystonia, sponsored by University of Florida. Completed at 1 site in United States. Open to participants aged 21 Years to 99 Years. Per ClinicalTrials.gov, last updated 2024-04-19.
Sponsored by University of Florida · Observational
The purpose of this study is to determine how common fatigue and sleepiness are in patients with dystonia.
The purpose of the study is to determine the prevalence of fatigue in patients with dystonia. There are many factors which may impact fatigue but perhaps the most important of these is sleep. It is therefore critical that we collect data on sleep habits and sleepiness to help interpret our data on fatigue. We will be using the Epworth Sleepiness Scale to assess daytime somnolence and the Parkinson's Disease Sleep Scale to assess the presence or absence of common sleep disorders affecting patients with movement disorders along with the Multidimensional Fatigue Inventory and the Fatigue Severity Scale.
319 studies on the registry are indexed under Dystonia; 56 are open to participants now.
This study's enrollment of 123 is above the median of 60 across 126 observational studies indexed under Dystonia.
Browse Dystonia studies →University of Florida is the lead sponsor of 1,254 studies on the registry; 201 are open to participants now.
Of its 170 completed or terminated interventional studies of FDA-regulated products, 136 (80%) have results posted.
Counted across the registry records on this site, refreshed daily.
Current dystonia patients in our clinic between the ages of 21 and 100.
Inclusion Criteria: diagnosis of dystonia
Exclusion Criteria:
Patients with dystonia, 21-100 years of age.
To determine the prevalence of fatigue and sleepiness in patients with dystonia.
Time frame: At the time of their visit.
This study is completed, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Florida